Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 11/20 | 0.53 |
| ▸ | NOS2 | P35228 | 7/20 | 0.53 |
| ▸ | NOS3 | P29474 | 5/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094155 | 0.83 | TDP1 (0.46) | NOS1NOS2NOS3ALDH1A1MAPT | |
| SCHEMBL9362866 | 0.82 | NOS1 (0.56) | NOS1NOS2NOS3PRKCIENPP2 | |
| SCHEMBL9362872 | 0.82 | NOS1 (0.56) | NOS1NOS2NOS3PRKCIENPP2 | |
| SCHEMBL13283718 | 0.80 | CYP4A11 (0.46) | NOS1NOS2NOS3 | |
| SCHEMBL8439706 | 0.78 | TRPA1 (0.42) | NOS1NOS2NOS3TSHRALDH1A1 | |
| SCHEMBL11982706 | 0.78 | SIGMAR1 (0.47) | NOS1NOS2 | |
| SCHEMBL8440754 | 0.78 | TSHR (0.46) | NOS1NOS2NOS3TSHR | |
| SCHEMBL10134884 | 0.78 | NOS1 (0.58) | NOS1NOS2NOS3ENPP2 | |
| SCHEMBL14028969 | 0.78 | NOS1 (0.36) | NOS1NOS2NOS3 | |
| SCHEMBL13715502 | 0.78 | NOS1 (0.41) | NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567143-B1 | ANTHRANILIC ACID AMIDES AND THE DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL AGENTS | SYMRISE AG (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| US-7939556-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-05-10 | — | — | US | disclosed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | NOS1 1769/4885NOS2 1689/4885NOS3 1487/4885 |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | P4HA1, CYP2R1, EGLN3 | NOS1 804/4885NOS2 846/4885NOS3 410/4885 |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | GABRB1, GABRB2, GABRB3 | NOS1 2439/4885NOS2 1862/4885NOS3 2231/4885 |
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | VHL, TPMT, NNMT | NOS1 2153/4885NOS2 1348/4885NOS3 1317/4885 |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | NOS1 1769/4885NOS2 1689/4885NOS3 1487/4885 |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | NOS1 3873/4885NOS2 3287/4885NOS3 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.